Extended Group Written Exposure Therapy for Comorbid PTSD and BPD (Traits)
4 mei 2026 bijgewerkt door: Jennifer Ip, St. Joseph's Healthcare Hamilton
The goal of this open label trial is to evaluate the effectiveness of virtual group extended Written Exposure Therapy (GE-WET) in reducing Post-Traumatic Stress Disorder (PTSD) symptoms in patients with comorbid PTSD and Borderline Personality Disorder (BPD) or BPD traits. GE-WET involves attending weekly 2-hour group WET sessions for the duration of 10 weeks, in which they write about their trauma experience using specific instructions.
This study will be conducted at St. Joseph's Healthcare Hamilton's Community Psychiatry Clinic with clients wait listed for PTSD treatment (ages 18- 65, any gender, co-morbid PTSD and BPD/BPD traits).
The main questions this study aims to answer are:
Does GE-WET reduce PTSD symptoms (based on PCL-5 measures) in this population (outpatient clients ages 18-65 of any gender, with a diagnosis of PTSD and BPD or BPD traits)?
Does GE-WET result in reduced drop-out rates for this population, compared to that of other evidence-based treatment for PTSD?
What are participants subjective experience of GE-WET?
Studie Overzicht
Toestand
Nog niet aan het werven
Interventie / Behandeling
Studietype
Ingrijpend
Inschrijving (Geschat)
63
Fase
- Niet toepasbaar
Contacten en locaties
In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.
Studie Locaties
-
-
Ontario
-
Hamilton, Ontario, Canada
- St. Joseph's Healthcare Hamilton
-
-
Deelname Criteria
Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Nee
Beschrijving
Inclusion Criteria:
- Reading and writing proficiency in English
- Access to an electronic device to attend virtual group meetings
- Age 18-65
- Previous diagnosis of Posttraumatic Stress Disorder (PTSD) and Borderline Personality Disorder (BPD)/BPD traits
- Completion of a DBT skills group via St. Joe's Community Psychiatry Clinic
Exclusion Criteria:
- Diagnosis of an active severe substance use disorder or psychotic disorder
- Untreated active psychotic symptoms, mania, or hypomania
- Has attempted suicide in the 2 months prior to treatment beginning
- Has engaged in high-risk self-harm (e.g., cutting, burning, asphyxiation) in the 2 months prior to beginning treatment
- Has completed Cognitive Processing Therapy or another active PTSD treatment (i.e., prolonged exposure) in the past year
Studie plan
Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Group Extended Written Exposure Therapy
Participants will be invited to participate in group extended Written Exposure Therapy (described in the Interventions section).
|
Group Extended Written Exposure Therapy (GE-WET) is a time-limited cognitive behavioural therapy for Posttraumatic Stress Disorder (PTSD) aimed at allowing patients to process their traumatic experiences in a safe environment.
GE-WET will consist of 10 weekly group sessions.
Participants will be asked to complete weekly in-session written exposures where they will recount their traumatic experience.
The written exposure will be followed by a guided discussion about the experience of writing the exposure.
There is no homework assigned between sessions.
However, group members will be asked to refrain from avoiding thinking about the trauma between sessions.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
PTSD Checklist for DSM-5 (PCL-5)
Tijdsspanne: From pre-treatment (1 week before the start of group) to one-month follow-up at about 4 months
|
From pre-treatment (1 week before the start of group) to one-month follow-up at about 4 months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Posttraumatic Cognitions Inventory
Tijdsspanne: From pre-treatment (1 week before the start of group) to one-month follow-up at about 4 months
|
A 36-item self-report questionnaire that assesses negative thoughts across three subscales: negative cognitions about the self (e.g., "I am a weak person"), negative cognitions about the world (e.g., "I have to be on guard all the time"), and self-blame (e.g., "the event happened because of the way I acted").
The PTCI has demonstrated good internal consistency, test-retest reliability, and convergent validity with other measures of posttraumatic cognitions.
|
From pre-treatment (1 week before the start of group) to one-month follow-up at about 4 months
|
|
Borderline Symptom List- Short Version (BSL-23)
Tijdsspanne: From pre-treatment (1 week before the start of group) to one-month follow-up at about 4 months
|
The BSL-23 is a 23-item self-report measure that assesses for DSM borderline personality disorder symptomatology as well as associated problems such as self-criticism, loneliness, helplessness, and problems with trust.
The BSL-23 has demonstrated high internal consistency and test-retest reliability, and strong convergent validity with correlations with depression and general psychopathology severity.
|
From pre-treatment (1 week before the start of group) to one-month follow-up at about 4 months
|
|
Borderline Symptom List Behaviour Supplement
Tijdsspanne: From pre-treatment (1 week before the start of group) to one-month follow-up at about 4 months
|
The BSL-23 Behaviour Supplement is an 11-item supplemental measure used to assess frequency of problematic behaviours (e.g., non-suicidal self-injury, suicide attempts, suicidal communication, angry outbursts, misuse of substances, etc.) associated with borderline personality disorder.
|
From pre-treatment (1 week before the start of group) to one-month follow-up at about 4 months
|
|
Toronto Alexithymia Scale-20 (TAS-20)
Tijdsspanne: From pre-treatment (1 week before the start of group) to one-month follow-up at about 4 months
|
The TAS-20 is a 20-item self-report measure assessing for alexithymia (i.e., issues in identifying and processing emotions) across three factors: difficulty identifying feelings, difficulty describing feelings, and externally-oriented thinking.
The TAS-20 has demonstrated adequate levels of convergent validity, good internal consistency, and good test-retest reliability.
|
From pre-treatment (1 week before the start of group) to one-month follow-up at about 4 months
|
|
Experience of Shame Scale (ESS)
Tijdsspanne: From pre-treatment (1 week before the start of group) to one-month follow-up at about 4 months
|
The ESS is a 25-item self-report measure assessing characterological shame (e.g., shame of personal habits or personal ability), behavioural shame (e.g., shame in doing or saying something wrong), and bodily shame (e.g., shame regarding one's body).
The ESS has demonstrated good internal consistency and test-retest reliability.
|
From pre-treatment (1 week before the start of group) to one-month follow-up at about 4 months
|
|
Difficulties in Emotion Regulation Scale (DERS)
Tijdsspanne: From pre-treatment (1 week before the start of group) to one-month follow-up at about 4 months
|
The DERS is a widely used 36-item self-report measure assessing six dimensions of emotion regulation difficulties.
The DERS demonstrates good internal consistency, convergent validity, and predictive validity of behaviours reflective of emotion regulation difficulties.
|
From pre-treatment (1 week before the start of group) to one-month follow-up at about 4 months
|
|
Group Cohesion Scale - Revised (GCS-R)
Tijdsspanne: Mid treatment (at about 5 weeks after start of group) and post treatment (at about 10 weeks)
|
The GCS-R is a self-report measure that measure's group member's perception of their group and the strength of the bonds formed.
The GCS-R showed high reliability for use in research and is sensitive to detecting changes in cohesiveness as a function of group development.
|
Mid treatment (at about 5 weeks after start of group) and post treatment (at about 10 weeks)
|
Medewerkers en onderzoekers
Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.
Sponsor
Publicaties en nuttige links
De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.
Algemene publicaties
- Bagby RM, Taylor GJ, Parker JD. The Twenty-item Toronto Alexithymia Scale--II. Convergent, discriminant, and concurrent validity. J Psychosom Res. 1994 Jan;38(1):33-40. doi: 10.1016/0022-3999(94)90006-x.
- Gratz, K. L., & Roemer, L. (2004). Multidimensional assessment of emotion regulation and dysregulation: Development, factor structure, and initial validation of the difficulties in emotion regulation scale. Journal of Psychopathology and Behavioral Assessment, 26, 41-54.
- Foa, E.B., Ehlers, A., Clark, D.M., Tolin, D.F., & Orsillo, S.M. (1999). The Posttraumatic Cognitions Inventory (PTCI): Development and validation. Psychological Assessment, 11(3), 303-314.
- Treadwell, T., Lavertue, N., Kumar, V. K., & Veeraraghavan, V. (2001). The Group Cohesion Scale-Revised: Reliability and validity. International Journal of Action Methods: Psychodrama, Skill Training, and Role Playing, 54(1), 3-12.
- Andrews B, Qian M, Valentine JD. Predicting depressive symptoms with a new measure of shame: The Experience of Shame Scale. Br J Clin Psychol. 2002 Mar;41(Pt 1):29-42. doi: 10.1348/014466502163778.
- Bohus M, Kleindienst N, Limberger MF, Stieglitz RD, Domsalla M, Chapman AL, Steil R, Philipsen A, Wolf M. The short version of the Borderline Symptom List (BSL-23): development and initial data on psychometric properties. Psychopathology. 2009;42(1):32-9. doi: 10.1159/000173701. Epub 2008 Nov 20.
Studie record data
Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.
Bestudeer belangrijke data
Studie start (Geschat)
1 juni 2026
Primaire voltooiing (Geschat)
1 juni 2028
Studie voltooiing (Geschat)
1 december 2028
Studieregistratiedata
Eerst ingediend
20 april 2026
Eerst ingediend dat voldeed aan de QC-criteria
4 mei 2026
Eerst geplaatst (Werkelijk)
8 mei 2026
Updates van studierecords
Laatste update geplaatst (Werkelijk)
8 mei 2026
Laatste update ingediend die voldeed aan QC-criteria
4 mei 2026
Laatst geverifieerd
1 mei 2026
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 18906
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
NEE
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Nee
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Nee
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .